Clinical Trials in Zabrze, Poland
47 recruiting
Showing 1–20 of 60 trials
Recruiting
Phase 3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Depressive Disorder, Major
Eli Lilly and Company1,000 enrolled186 locationsNCT07412756
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
Hoffmann-La Roche120 enrolled93 locationsNCT05503264
Recruiting
Phase 3
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
Chronic Coronary SyndromeStable Coronary Artery Disease CAD
Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.1,703 enrolled18 locationsNCT07195149
Recruiting
Phase 3
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Diabetes Mellitus, Type 1
Novo Nordisk A/S877 enrolled193 locationsNCT07076199
Recruiting
Phase 2Phase 3
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Agitation Associated With Alzheimer's Disease Dementia
Exciva GmbH300 enrolled49 locationsNCT07284472
Recruiting
Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Alzheimers Disease
Hoffmann-La Roche13,000 enrolled211 locationsNCT07177352
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled159 locationsNCT07282600
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled169 locationsNCT07321886
Recruiting
Phase 3
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Alzheimers Disease
Hoffmann-La Roche800 enrolled143 locationsNCT07169578
Recruiting
Trifecta-Heart cfDNA-MMDx Study
heart transplant rejection
University of Alberta300 enrolled12 locationsNCT04707872
Recruiting
Not Applicable
Implementation of a Pediatric ERAS-based Protocol in Intestinal Resection With Primary Anastomosis
Intestinal DiseasesIntestinal Resection
Michał Pasierbek120 enrolled9 locationsNCT07504549
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Secondary-progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals1,275 enrolled208 locationsNCT07225504
Recruiting
Phase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled47 locationsNCT05877963
Recruiting
Phase 3
A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy
Bowel Cleansing Prior to Clinical Procedures
Norgine212 enrolled41 locationsNCT07218523
Recruiting
Not Applicable
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
Atrial Fibrillation (AF)Persistent Atrial FibrillationParoxysmal AF
Abbott Medical Devices240 enrolled13 locationsNCT07523620
Recruiting
Phase 2
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
Hoffmann-La Roche182 enrolled56 locationsNCT07074886
Recruiting
Not Applicable
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
HypertensionHypertension, SystolicHypertension,Essential
Orchestra BioMed, Inc500 enrolled129 locationsNCT06059638
Recruiting
Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
Multiple Sclerosis
Hoffmann-La Roche129 enrolled32 locationsNCT05704361
Recruiting
Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Progressive Multiple Sclerosis
Hoffmann-La Roche360 enrolled73 locationsNCT07282574
Recruiting
Phase 3
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany264 enrolled138 locationsNCT06463587